These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 30878103)

  • 1. Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial.
    Alexandrov AV; Köhrmann M; Soinne L; Tsivgoulis G; Barreto AD; Demchuk AM; Sharma VK; Mikulik R; Muir KW; Brandt G; Alleman J; Grotta JC; Levi CR; Molina CA; Saqqur M; Mavridis D; Psaltopoulou T; Vosko M; Fiebach JB; Mandava P; Kent TA; Alexandrov AW; Schellinger PD;
    Lancet Neurol; 2019 Apr; 18(4):338-347. PubMed ID: 30878103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial.
    Schellinger PD; Alexandrov AV; Barreto AD; Demchuk AM; Tsivgoulis G; Kohrmann M; Alleman J; Howard V; Howard G; Alexandrov AW; Brandt G; Molina CA;
    Int J Stroke; 2015 Oct; 10(7):1141-8. PubMed ID: 26120902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLOTBUST-Hands Free: pilot safety study of a novel operator-independent ultrasound device in patients with acute ischemic stroke.
    Barreto AD; Alexandrov AV; Shen L; Sisson A; Bursaw AW; Sahota P; Peng H; Ardjomand-Hessabi M; Pandurengan R; Rahbar MH; Barlinn K; Indupuru H; Gonzales NR; Savitz SI; Grotta JC
    Stroke; 2013 Dec; 44(12):3376-81. PubMed ID: 24159060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pragmatic approach to sonothrombolysis in acute ischaemic stroke: the Norwegian randomised controlled sonothrombolysis in acute stroke study (NOR-SASS).
    Nacu A; Kvistad CE; Logallo N; Naess H; Waje-Andreassen U; Aamodt AH; Solhoff R; Lund C; Tobro H; Rønning OM; Salvesen R; Idicula TT; Thomassen L
    BMC Neurol; 2015 Jul; 15():110. PubMed ID: 26162826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
    Gusev EI; Martynov MY; Nikonov AA; Shamalov NA; Semenov MP; Gerasimets EA; Yarovaya EB; Semenov AM; Archakov AI; Markin SS;
    Lancet Neurol; 2021 Sep; 20(9):721-728. PubMed ID: 34418399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
    Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
    Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial.
    Parsons MW; Yogendrakumar V; Churilov L; Garcia-Esperon C; Campbell BCV; Russell ML; Sharma G; Chen C; Lin L; Chew BL; Ng FC; Deepak A; Choi PMC; Kleinig TJ; Cordato DJ; Wu TY; Fink JN; Ma H; Phan TG; Markus HS; Molina CA; Tsai CH; Lee JT; Jeng JS; Strbian D; Meretoja A; Arenillas JF; Buck BH; Devlin MJ; Brown H; Butcher KS; O'Brien B; Sabet A; Wijeratne T; Bivard A; Grimley RS; Agarwal S; Munshi SK; Donnan GA; Davis SM; Miteff F; Spratt NJ; Levi CR;
    Lancet Neurol; 2024 Aug; 23(8):775-786. PubMed ID: 38880118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.
    Goyal M; Menon BK; van Zwam WH; Dippel DW; Mitchell PJ; Demchuk AM; Dávalos A; Majoie CB; van der Lugt A; de Miquel MA; Donnan GA; Roos YB; Bonafe A; Jahan R; Diener HC; van den Berg LA; Levy EI; Berkhemer OA; Pereira VM; Rempel J; Millán M; Davis SM; Roy D; Thornton J; Román LS; Ribó M; Beumer D; Stouch B; Brown S; Campbell BC; van Oostenbrugge RJ; Saver JL; Hill MD; Jovin TG;
    Lancet; 2016 Apr; 387(10029):1723-31. PubMed ID: 26898852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
    Logallo N; Novotny V; Assmus J; Kvistad CE; Alteheld L; Rønning OM; Thommessen B; Amthor KF; Ihle-Hansen H; Kurz M; Tobro H; Kaur K; Stankiewicz M; Carlsson M; Morsund Å; Idicula T; Aamodt AH; Lund C; Næss H; Waje-Andreassen U; Thomassen L
    Lancet Neurol; 2017 Oct; 16(10):781-788. PubMed ID: 28780236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
    Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.
    Hacke W; Kaste M; Fieschi C; von Kummer R; Davalos A; Meier D; Larrue V; Bluhmki E; Davis S; Donnan G; Schneider D; Diez-Tejedor E; Trouillas P
    Lancet; 1998 Oct; 352(9136):1245-51. PubMed ID: 9788453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
    Menon BK; Buck BH; Singh N; Deschaintre Y; Almekhlafi MA; Coutts SB; Thirunavukkarasu S; Khosravani H; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar J; Williams H; Field TS; Manosalva A; Siddiqui M; Zafar A; Imoukhuede O; Hunter G; Demchuk AM; Mishra S; Gioia LC; Jalini S; Cayer C; Phillips S; Elamin E; Shoamanesh A; Subramaniam S; Kate M; Jacquin G; Camden MC; Benali F; Alhabli I; Bala F; Horn M; Stotts G; Hill MD; Gladstone DJ; Poppe A; Sehgal A; Zhang Q; Lethebe BC; Doram C; Ademola A; Shamy M; Kenney C; Sajobi TT; Swartz RH;
    Lancet; 2022 Jul; 400(10347):161-169. PubMed ID: 35779553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
    Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
    Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial.
    Muir KW; Ford GA; Ford I; Wardlaw JM; McConnachie A; Greenlaw N; Mair G; Sprigg N; Price CI; MacLeod MJ; Dima S; Venter M; Zhang L; O'Brien E; Sanyal R; Reid J; Sztriha LK; Haider S; Whiteley WN; Kennedy J; Perry R; Lakshmanan S; Chakrabarti A; Hassan A; Marigold R; Raghunathan S; Sims D; Bhandari M; Wiggam I; Rashed K; Douglass C;
    Lancet Neurol; 2024 Nov; 23(11):1087-1096. PubMed ID: 39424558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
    Wang Y; Li S; Pan Y; Li H; Parsons MW; Campbell BCV; Schwamm LH; Fisher M; Che F; Dai H; Li D; Li R; Wang J; Wang Y; Zhao X; Li Z; Zheng H; Xiong Y; Meng X;
    Lancet; 2023 Feb; 401(10377):645-654. PubMed ID: 36774935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
    Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW
    Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
    Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L
    Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
    ; Sandercock P; Wardlaw JM; Lindley RI; Dennis M; Cohen G; Murray G; Innes K; Venables G; Czlonkowska A; Kobayashi A; Ricci S; Murray V; Berge E; Slot KB; Hankey GJ; Correia M; Peeters A; Matz K; Lyrer P; Gubitz G; Phillips SJ; Arauz A
    Lancet; 2012 Jun; 379(9834):2352-63. PubMed ID: 22632908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial.
    Bornstein NM; Saver JL; Diener HC; Gorelick PB; Shuaib A; Solberg Y; Thackeray L; Savic M; Janelidze T; Zarqua N; Yarnitsky D; Molina CA;
    Lancet; 2019 Jul; 394(10194):219-229. PubMed ID: 31133406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.